Harvard Bioscience (HBIO) Cost of Revenue (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Cost of Revenue data on file, last reported at $235000.0 in Q1 2026.

• On a quarterly basis, Cost of Revenue fell 97.55% year-over-year to $235000.0 in Q1 2026; TTM through Mar 2026 was -$25.9 million, a 187.41% decrease from a year earlier, with the FY2025 full-year figure at $729000.0, down 98.15% from the prior year.
• Cost of Revenue for Q1 2026 stood at $235000.0, up from -$26.3 million in the prior quarter.
• Over the last five years, Cost of Revenue for HBIO reached as high as $14.8 million in Q3 2022 and fell as low as -$26.3 million in Q4 2025.
• Historically, Cost of Revenue has averaged $5.3 million across 5 years, with a median of $9.6 million in 2025.
• On a YoY basis, Cost of Revenue climbed as much as 892.75% in 2025 and fell as far as 349.86% in 2025.
• Year by year, Cost of Revenue stood at $12.6 million in 2022, then slipped by 6.08% to $11.8 million in 2023, then dropped by 10.85% to $10.5 million in 2024, then tumbled by 349.86% to -$26.3 million in 2025, then soared by 100.89% to $235000.0 in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $235000.0 in Q1 2026, -$26.3 million in Q4 2025, and $48000.0 in Q3 2025.